REFERENCES
1. M.E. Donohoe ME. Results Probl. Cell Differ. 55, 231–45 (2012).
2. K. Banno et al., Biochem. Res. Int. onlline, DOI :10.1155/2012/738274 738274, February, 2012.
3. Y. Boumber and J.P. Issa, Oncology 25 (3), 220–228 (2011).
4. P. Lopez-Serra and M. Esteller, Oncogene 31 (13), 1609–1622 (2012).
5. M. Esteller, N. Eng. J. Med. 358, 1148–1159 (2008).
6. P. Ao et al., Med. Hypotheses 70 (3), 678–684 (2008).
7. S.K. Bolta et al., Breast Cancer Res. Treat.
135 (3), 705–13 (2012).
8. Cai et al., Int. J. Mol. Sci. 12 (7), 4465–4487 (2012).
9. S.B. Baylin and P.A. Jones, Nat. Rev. Cancer 11 (10), 726–734 (2011).
10. M. Tessema et al., Carcinogenesis 30 (7), 1132–1138 (2009).
11. J.M Yingling JM, "The Changing Field of Drug Development," online Jul. 16, 2012.
http://ecancer.org/tv/subject/611/1547/video.10 accessed Dec. 13, 2012.
12. P. Cuatrecasas, J. Clin. Invest. 116 (11), 2837–2842 (2006).
13. T. Kubota, K. Miyake, and T. Hirasawa, Clin. Epigenetics 4 (1), 1 (2012).
14. K.J. Morrow, Kalorama Reports, Pub ID: KLI3860511, pg. 160 (2012).
|
